ReviewClinical rheumatology2020
The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach.
Review in Clinical rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- The risks of autoimmune inflammatory outcomes in patients infected with SARS-CoV-2: a longitudinal, population-based cohort study.International journal of surgery (London, England) · 2025Article
- Clinical Activity of Behcet's Disease Associated with SARS-CoV-2 and Herpes Simplex Virus: Insights from Three Case Reports.International medical case reports journal · 2025Article
- Henoch-Schönlein purpura following mRNA COVID-19 vaccination: a case report.Clinical and experimental vaccine research · 2024Article
- The correlation between corona virus disease 2019 and alopecia areata: a literature review.Frontiers in immunology · 2024Review
- Onset of Type I Diabetes Followed by Scleroderma Syndrome in a Child After the COVID-19: A Case Report.Global pediatric health · 2024Article
- Mitochondrial N-formyl methionine peptides contribute to exaggerated neutrophil activation in patients with COVID-19.Virulence · 2023Article
- Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19.JAMA network open · 2023Article
- Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study.EClinicalMedicine · 2023Article
- COVID-19 and inflammatory bowel disease crosstalk: From emerging association to clinical proposal.Journal of medical virology · 2022Review
- A Review Pertaining to SARS-CoV-2 and Autoimmune Diseases: What Is the Connection?Life (Basel, Switzerland) · 2022Review
- Molecular mimicry, hyperactive immune system, and SARS-COV-2 are three prerequisites of the autoimmune disease triangle following COVID-19 infection.International immunopharmacology · 2022Review
- Dysregulation of immunity in COVID-19 and SLE.Inflammopharmacology · 2022Review
- Relationship Between BMI and Disease Severity in COVID-19 Patients.Anesthesiology and pain medicine · 2022Article
- SARS-CoV-2 triggering autoimmune diseases.Cytokine · 2022Review
- Systems biology models to identify the influence of SARS-CoV-2 infections to the progression of human autoimmune diseases.Informatics in medicine unlocked · 2022Article
- Multisystem Inflammatory Syndrome and Autoimmune Diseases Following COVID-19: Molecular Mechanisms and Therapeutic Opportunities.Frontiers in molecular biosciences · 2022Review
- COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges.Cells · 2021Review
- The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies.Cytokine & growth factor reviews · 2021Review
- Similarities between COVID-19 and systemic sclerosis early vasculopathy: A "viral" challenge for future research in scleroderma.Autoimmunity reviews · 2021Review
- Arthritis after SARS-CoV-2 infection.The Lancet. Rheumatology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytokine pathways and their signaling disorders can be the cause of onset and pathogenesis of many diseases such as autoimmune diseases and COVID-19 infection. Autoimmune patients may be at higher risk of developing infection due to the impaired immune responses, the use of immunosuppressive drugs, and damage to various organs. Increased secretion of inflammatory cytokines and intolerance of the patient's immune system to COVID-19 infection are the leading causes of hospitalization of these patients. The content used in this paper has been taken from English language articles (2005-2020) retrieved from the PubMed database and Google Scholar search engine using "COVID-19," "Autoimmune disease," "Therapeutic," "Pathogenesis," and "Pathway" keywords. The emergence of COVID-19 and its association with autoimmune disorders is a major challenge in the management of these diseases. The results showed that the use of corticosteroids in the treatment of autoimmune diseases can make diagnosis and treatment of COVID-19 more challenging by preventing the fever. Due to the common pathogenesis of COVID-19 and autoimmune diseases, the use of autoimmune drugs as a possible treatment option could help control the virus. KEY POINTS: • Inflammatory cytokines play an essential role in the pathogenesis of COVID-19 • ACE2 dysfunctions are related to the with COVID-19 and autoimmune diseases • The use autoimmune diseases drugs can be useful in treating COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.